MX378591B - Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico - Google Patents
Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolicoInfo
- Publication number
- MX378591B MX378591B MX2018014164A MX2018014164A MX378591B MX 378591 B MX378591 B MX 378591B MX 2018014164 A MX2018014164 A MX 2018014164A MX 2018014164 A MX2018014164 A MX 2018014164A MX 378591 B MX378591 B MX 378591B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- intermediates
- synthesis
- obeticholic
- acid derivatives
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 title 1
- 229960001601 obeticholic acid Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003613 bile acid Substances 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608777.7A GB201608777D0 (en) | 2016-05-18 | 2016-05-18 | Compounds |
| PCT/GB2017/051385 WO2017199033A1 (en) | 2016-05-18 | 2017-05-18 | Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014164A MX2018014164A (es) | 2019-04-01 |
| MX378591B true MX378591B (es) | 2025-03-11 |
Family
ID=56320629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014164A MX378591B (es) | 2016-05-18 | 2017-05-18 | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10968250B2 (OSRAM) |
| EP (2) | EP3848382B1 (OSRAM) |
| JP (1) | JP7034093B2 (OSRAM) |
| KR (1) | KR102458265B1 (OSRAM) |
| CN (1) | CN109415407B (OSRAM) |
| AU (1) | AU2017266539B2 (OSRAM) |
| CA (1) | CA3024281A1 (OSRAM) |
| EA (1) | EA037584B1 (OSRAM) |
| ES (2) | ES2970336T3 (OSRAM) |
| GB (1) | GB201608777D0 (OSRAM) |
| HR (1) | HRP20211128T1 (OSRAM) |
| HU (1) | HUE054851T2 (OSRAM) |
| MX (1) | MX378591B (OSRAM) |
| PT (1) | PT3458469T (OSRAM) |
| WO (1) | WO2017199033A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| EP3431486A1 (en) * | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN111138509B (zh) * | 2018-11-02 | 2022-12-06 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的制备方法 |
| CN111072744B (zh) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成熊去氧胆酸的方法 |
| CN114315945A (zh) * | 2020-09-28 | 2022-04-12 | 四川澄华生物科技有限公司 | 一种胆甾酸及其衍生物的除杂方法 |
| CN112341516B (zh) * | 2020-11-14 | 2022-07-15 | 湖南科瑞生物制药股份有限公司 | 5,6-环氧类固醇类化合物及其制备方法和应用 |
| US20250296949A1 (en) * | 2021-11-02 | 2025-09-25 | Sandhill One, Llc | High purity non-animal derived udca |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624748A (en) | 1950-09-09 | 1953-01-06 | Upjohn Co | Bisnorchola-4, 6-dien-3-one-22-al |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| DE69312700T2 (de) | 1992-04-14 | 1998-02-19 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
| WO1994019366A1 (en) | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| DE60205891T2 (de) | 2001-03-12 | 2006-06-22 | Intercept Pharmaceuticals, Inc. | Steroide als agonisten für fxr |
| US20090062256A1 (en) | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| JP4758608B2 (ja) | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | 分枝ポリマーおよびそれらの結合体 |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| CN101374854A (zh) * | 2006-01-12 | 2009-02-25 | 三菱化学株式会社 | 甾类化合物的制备方法 |
| JP2007210888A (ja) * | 2006-01-12 | 2007-08-23 | Mitsubishi Chemicals Corp | ステロイド化合物の製造方法 |
| BRPI0707794A2 (pt) | 2006-02-14 | 2011-05-10 | Intercept Pharmaceuticals Inc | compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos |
| PL2040713T3 (pl) | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals Inc | Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR |
| BRPI0808684B1 (pt) | 2007-01-19 | 2021-08-10 | Intercept Pharmaceuticals, Inc | Compostos moduladores de tgr5, composição e seus usos |
| US8796249B2 (en) | 2008-07-30 | 2014-08-05 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| PL2698375T3 (pl) | 2008-11-19 | 2018-08-31 | Intercept Pharmaceuticals, Inc. | Modulatory TGR5 i sposób ich zastosowania |
| ES2774368T3 (es) | 2008-11-19 | 2020-07-20 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos de uso de los mismos |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| PT3336097T (pt) | 2012-06-19 | 2020-10-29 | Intercept Pharmaceuticals Inc | Preparação da forma não cristalina de ácido obeticólico |
| CN108250264A (zh) | 2012-10-26 | 2018-07-06 | 英特塞普特医药品公司 | 制备胆汁酸衍生物的方法 |
| NZ708501A (en) | 2012-11-28 | 2019-03-29 | Intercept Pharmaceuticals Inc | Treatment of pulmonary disease |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| EA030152B1 (ru) | 2013-05-14 | 2018-06-29 | Интерсепт Фармасьютикалз, Инк | 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов |
| RU2015155552A (ru) | 2013-05-24 | 2017-06-27 | Нестек С.А. | Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника |
| US10166246B2 (en) * | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| LT3149019T (lt) | 2014-05-29 | 2020-02-25 | Bar Pharmaceuticals S.R.L. | Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai |
| EP3215179A4 (en) | 2014-11-06 | 2018-07-25 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| WO2016079519A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| EA033603B1 (ru) | 2014-11-19 | 2019-11-08 | Nzp Uk Ltd | 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| WO2016079517A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
| EA033445B1 (ru) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| JP2017535570A (ja) | 2014-11-26 | 2017-11-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN106279328A (zh) | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
| JP6861703B2 (ja) | 2015-06-19 | 2021-04-21 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｔｇｒ５修飾物質およびその使用方法 |
| CN106397522A (zh) | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106478756A (zh) | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
| GB201608779D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
-
2016
- 2016-05-18 GB GBGB1608777.7A patent/GB201608777D0/en not_active Ceased
-
2017
- 2017-05-18 PT PT177257409T patent/PT3458469T/pt unknown
- 2017-05-18 CA CA3024281A patent/CA3024281A1/en active Pending
- 2017-05-18 HR HRP20211128TT patent/HRP20211128T1/hr unknown
- 2017-05-18 EP EP21160246.1A patent/EP3848382B1/en active Active
- 2017-05-18 WO PCT/GB2017/051385 patent/WO2017199033A1/en not_active Ceased
- 2017-05-18 ES ES21160246T patent/ES2970336T3/es active Active
- 2017-05-18 ES ES17725740T patent/ES2878577T3/es active Active
- 2017-05-18 EA EA201892514A patent/EA037584B1/ru unknown
- 2017-05-18 EP EP17725740.9A patent/EP3458469B1/en active Active
- 2017-05-18 MX MX2018014164A patent/MX378591B/es unknown
- 2017-05-18 CN CN201780030532.1A patent/CN109415407B/zh active Active
- 2017-05-18 JP JP2018560597A patent/JP7034093B2/ja active Active
- 2017-05-18 HU HUE17725740A patent/HUE054851T2/hu unknown
- 2017-05-18 US US16/302,059 patent/US10968250B2/en active Active
- 2017-05-18 KR KR1020187035834A patent/KR102458265B1/ko active Active
- 2017-05-18 AU AU2017266539A patent/AU2017266539B2/en active Active
-
2021
- 2021-02-26 US US17/186,272 patent/US11479577B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018014164A (es) | 2019-04-01 |
| CN109415407A (zh) | 2019-03-01 |
| WO2017199033A1 (en) | 2017-11-23 |
| AU2017266539A1 (en) | 2018-11-15 |
| AU2017266539B2 (en) | 2021-04-15 |
| US10968250B2 (en) | 2021-04-06 |
| US20210179661A1 (en) | 2021-06-17 |
| ES2970336T3 (es) | 2024-05-28 |
| PT3458469T (pt) | 2021-06-11 |
| CN109415407B (zh) | 2021-08-17 |
| EA201892514A1 (ru) | 2019-05-31 |
| ES2878577T3 (es) | 2021-11-19 |
| EP3848382B1 (en) | 2023-11-29 |
| HUE054851T2 (hu) | 2021-10-28 |
| EP3848382A1 (en) | 2021-07-14 |
| EA037584B1 (ru) | 2021-04-16 |
| KR102458265B1 (ko) | 2022-10-25 |
| HRP20211128T1 (hr) | 2022-01-07 |
| JP2019516720A (ja) | 2019-06-20 |
| CA3024281A1 (en) | 2017-11-23 |
| BR112018073488A2 (pt) | 2019-04-09 |
| KR20190009322A (ko) | 2019-01-28 |
| GB201608777D0 (en) | 2016-06-29 |
| EP3458469A1 (en) | 2019-03-27 |
| EP3458469B1 (en) | 2021-04-14 |
| EP3848382C0 (en) | 2023-11-29 |
| US11479577B2 (en) | 2022-10-25 |
| JP7034093B2 (ja) | 2022-03-11 |
| US20190284227A1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378591B (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico | |
| PH12017502331A1 (en) | 1,4-substituted piperidine derivatives | |
| IN2014KN00929A (OSRAM) | ||
| TN2019000192A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| MX2020003458A (es) | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. | |
| EP4321513A3 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| WO2014164533A8 (en) | Methods of stereoselective synthesis of substituted nucleoside analogs | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| WO2016168682A3 (en) | Bromodomain inhibitor | |
| MX378717B (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble. | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| EA201691794A1 (ru) | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MX350211B (es) | Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico. | |
| PH12017501043A1 (en) | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MX379846B (es) | Derivados de 4-bencil y 4-benzoil piperidina sustituidos. | |
| MX387443B (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| MX377644B (es) | 6.7.beta-epóxidos esteroideos como intermedios químicos. | |
| MX378555B (es) | Proceso para la preparacion de derivados del acido biliar de las sulfonilureas | |
| MX392586B (es) | Derivados de la espiropiperidina. | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones |